Elimination Diets Call for Caution and Adaptation

AUGUST 26, 2025

New Strategy Proposed for HR+, HER2– Advanced Breast Cancer

AUGUST 26, 2025

Keeping an Eye on 8 New Payment Trends

AUGUST 25, 2025

Email This Article

POSTED: MAY 8, 2018

Tafinlar-Mekinist Approved for BRAF-Positive Anaplastic Thyroid Cancer

The FDA approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the treatment of unresectable or metastatic anaplastic thyroid cancer (ATC) with the BRAF V600E mutation.
A link to this article will be included in this email.

Recipient's Email Address:

Enter email addresses separated by commas if sending to more than one person. (200 characters max)

Your Name:

Your Email Address:

Send me a copy

Personal Message: (Optional)

These email addresses will only be used to send out this message.

Please wait..

FDA News

MAY 8, 2018

Tafinlar-Mekinist Approved for BRAF-Positive Anaplastic Thyroid Cancer

To read the full story, Log in or Sign up for a Free Account

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select